Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures

摘要

Background Topical hemostatic agents are used to reduce bleeding and transfusion need during cardiothoracic surgery. We report our experience with Arista? AH Absorbable Hemostatic Particles (Arista? AH), a novel plant-based microporous polysaccharide hemostatic powder. Methods Data were retrospectively collected for patients (n?=?240) that received cardiothoracic surgery at our institution from January 2009 to January 2013 with (n?=?103) or without (n?=?137) the use of Arista? AH. Endpoints included protamine to skin closure time (hemostasis time), cardiopulmonary bypass time, quantity of Arista? AH applied, intraoperative blood product usage, intraoperative blood loss, chest tube output 48 hours postoperatively, blood products required 48 hours postoperatively, length of stay in the intensive care unit, 30-day morbidity, and 30-day mortality. Results 240 patients (176 M: 64 F) underwent 240 cardiothoracic procedures including heart transplantation (n?=?53), cardiac assist devices (n?=?113), coronary artery bypass grafts (n?=?20), valve procedures (n?=?19), lung transplantation (n?=?17), aortic dissection (n?=?8), and other (n?=?10). Application of Arista? AH led to significant reduction in hemostasis time versus the untreated control group (Arista? AH: 93.4?±?41 min. vs. Control: 107.6?±?56 min., p?=?0.02). Postoperative chest tube output in the first 48 hours was also significantly reduced (Arista? AH: 1594?±?949 mL vs. Control: 2112?±?1437 mL, p?